版本:
中国

BRIEF-Neurocrine announces FDA approval of Ingrezza TM (valbenazine) capsules

April 11 Neurocrine Biosciences Inc:

* Neurocrine announces FDA approval of Ingrezza TM (valbenazine) capsules as the first and only approved treatment for adults with tardive dyskinesia (TD)

* Neurocrine Biosciences Inc- "Ingrezza will be in distribution channel next week and will be available through a select pharmacy network" Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐